Subramanian 2013
| Methods | RCT | |
| Participants | Study took place in Canada 32 participants: 16 intervention, 16 control Inclusion criteria: between 40 and 80 years, sustained single ischaemic or haemorrhagic stroke 6 to 60 months previously, scored 3 to 6 on the Chedoke McMaster Stroke Assessment arm subscale and had no other neurologic or neuromuscular/orthopaedic problems affecting the upper limb and trunk Exclusion criteria: brainstem or cerebellar lesions, comprehension difficulties and marked apraxia, attention or visual field deficits Mean (SD) age: intervention group 62 (9.7), control group 60 (11) years 72% male Stroke details: 47% right hemiparesis Timing post stroke: intervention group mean (SD) 3.7 (2.2) years, control group 3.0 (1.9) years |
|
| Interventions | Virtual reality intervention: a 3D virtual environment (CAREN system) simulated a supermarket scene. Participants had to reach for objects in the virtual environment. Training was high in intensity with 72 trials of reaching in each session Control intervention: pointing at targets in a physical environment Sessions were 45 minutes for 12 days spaced over 4 weeks |
|
| Outcomes | Outcomes were recorded at baseline, post‐intervention and 3 months following intervention Upper limb outcomes: Fugl Meyer, Reaching Performance Scale for Stroke, Wolf Motor Function Test Other outcomes: Motor Activity Log‐AS Other outcomes: Motivation Task Evaluation Questionnaire Other outcomes: kinematic data |
|
| Notes | — | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Computer‐generated |
| Allocation concealment (selection bias) | Low risk | Managed by external personnel |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk | Blinded to allocation |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | All completed the assessments. Small number of intervention drop outs and balanced across groups |
| Selective reporting (reporting bias) | Low risk | All outcomes reported as per entry on clinical trial registry |